Elicio Therapeutics, Inc.

NASDAQ
ELTX
paper.types.company
Rentabilité sur six mois: -13.73%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions Elicio Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.

plus de détails
It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-02-05
ISIN
US28657F1030
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV -5.5 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA -187.61 0
ROE -170157.38 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.5181 10
Debt/Ratio 0.9241 9
Debt/Equity -3.49 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 875.86 10
Rentabilité Ebitda, % 224.29 10
Rentabilité EPS, % 120.36 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 7.6 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 7.94 $ 7.6 $ 8.02 $ -4.22 % 0 % 0 %
common.calendar.number_days.30d 5.66 $ 5.15 $ 8.1 $ 34.28 % 0 % 0 %
common.calendar.number_days.90d 5 $ 4.76 $ 8.75 $ 52 % 0 % 0 %
common.calendar.number_days.180d 8.81 $ 4.76 $ 9.64 $ -13.73 % 0 % 0 %
common.calendar.number_days.1y 3.98 $ 3.39 $ 9.64 $ 90.95 % 0 % 0 %
common.calendar.number_days.3y 10.2 $ 0.988 $ 18.15 $ -25.49 % 0 % 0 %
common.calendar.number_days.5y 0 $ 0.988 $ 25.74 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.988 $ 25.74 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 8.17 $ 4.76 $ 9.64 $ -6.98 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Robert T. Connelly CEO, President & Director 612k 1960 (65 années)
Dr. Christopher M. Haqq M.D., Ph.D. Executive VP, Head of Research & Development and Chief Medical Officer 589k 1966 (59 années)
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board N/A
Mr. Michael DiVecchia Senior Vice President of Operations & Human Resources N/A
Dr. Peter DeMuth Ph.D. Chief Scientific Officer N/A 1986 (39 années)
Ms. Esther Welkowsky Senior Vice President of Clinical Development N/A
Ms. Joy Seymour VP & Head of Regulatory Affairs N/A
Ms. Megan C. Filoon General Counsel, Secretary & Compliance Officer N/A
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics N/A

Informations sur l'entreprise

Adresse: United States, Boston. MA, 451 D Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://elicio.com